MA39447B1 - Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine - Google Patents

Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Info

Publication number
MA39447B1
MA39447B1 MA39447A MA39447A MA39447B1 MA 39447 B1 MA39447 B1 MA 39447B1 MA 39447 A MA39447 A MA 39447A MA 39447 A MA39447 A MA 39447A MA 39447 B1 MA39447 B1 MA 39447B1
Authority
MA
Morocco
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
medicine
pain
Prior art date
Application number
MA39447A
Other languages
English (en)
Other versions
MA39447A1 (fr
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Damil
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MA39447A1 publication Critical patent/MA39447A1/fr
Publication of MA39447B1 publication Critical patent/MA39447B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne le composé (s)-pirlindole ou ses sels pharmaceutiquement acceptables, ainsi que des compositions pharmaceutiques comprenant ceux-ci pour une utilisation dans le traitement thérapeutique et la prévention de la douleur.
MA39447A 2014-05-09 2014-05-09 Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine MA39447B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000029 WO2015171005A1 (fr) 2014-05-09 2014-05-09 (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Publications (2)

Publication Number Publication Date
MA39447A1 MA39447A1 (fr) 2017-10-31
MA39447B1 true MA39447B1 (fr) 2018-05-31

Family

ID=50819931

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39447A MA39447B1 (fr) 2014-05-09 2014-05-09 Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Country Status (29)

Country Link
US (1) US9814712B2 (fr)
EP (1) EP3057589B1 (fr)
JP (1) JP6768520B2 (fr)
KR (1) KR102298676B1 (fr)
CN (1) CN106456637B (fr)
AU (1) AU2014393490B2 (fr)
CA (1) CA2948598C (fr)
CY (1) CY1119532T1 (fr)
DK (1) DK3057589T3 (fr)
EC (1) ECSP16086247A (fr)
ES (1) ES2649492T3 (fr)
HR (1) HRP20171651T1 (fr)
HU (1) HUE035071T2 (fr)
IL (1) IL248855B (fr)
LT (1) LT3057589T (fr)
MA (1) MA39447B1 (fr)
MX (1) MX368734B (fr)
NO (1) NO3057589T3 (fr)
NZ (1) NZ726132A (fr)
PH (1) PH12016502233A1 (fr)
PL (1) PL3057589T3 (fr)
PT (1) PT3057589T (fr)
RS (1) RS56591B1 (fr)
RU (1) RU2695647C2 (fr)
SA (1) SA516380264B1 (fr)
SI (1) SI3057589T1 (fr)
TN (1) TN2016000498A1 (fr)
UA (1) UA118474C2 (fr)
WO (1) WO2015171005A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6400121B2 (ja) * 2014-05-09 2018-10-03 テクニメデ ソシエダーデ テクニコ−メディシナル エス.アー. 医療用のピルリンドールエナンチオマーの薬学的に許容可能な塩
MA39448B1 (fr) * 2014-05-09 2019-12-31 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP3392251A1 (fr) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation des enantiomères de pirlindole et leurs sels
EP3392250A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole
MX2018011142A (es) 2018-09-13 2019-10-10 Federico Amezcua Amezcua Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
EP3900716A1 (fr) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-cristal de gabapentine, de kétoprofène et de lysine, compositions pharmaceutiques et leur utilisation médicale

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
CA2511599A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide
WO2005025550A1 (fr) * 2003-09-15 2005-03-24 Vectura Limited Compositions pharmaceutiques permettant de traiter l'ejaculation precoce par inhalation pulmonaire
EP1688161A1 (fr) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
JP6400121B2 (ja) * 2014-05-09 2018-10-03 テクニメデ ソシエダーデ テクニコ−メディシナル エス.アー. 医療用のピルリンドールエナンチオマーの薬学的に許容可能な塩

Also Published As

Publication number Publication date
ECSP16086247A (es) 2017-02-24
SI3057589T1 (sl) 2017-12-29
JP6768520B2 (ja) 2020-10-14
AU2014393490B2 (en) 2020-01-02
HRP20171651T1 (hr) 2017-12-15
CN106456637A (zh) 2017-02-22
MA39447A1 (fr) 2017-10-31
IL248855B (en) 2020-05-31
RS56591B1 (sr) 2018-02-28
SA516380264B1 (ar) 2019-07-29
KR20170002434A (ko) 2017-01-06
NO3057589T3 (fr) 2017-12-30
MX2016014699A (es) 2017-05-02
HUE035071T2 (en) 2018-05-02
UA118474C2 (uk) 2019-01-25
PH12016502233A1 (en) 2017-02-06
CY1119532T1 (el) 2018-03-07
MX368734B (es) 2019-10-14
PT3057589T (pt) 2017-11-29
RU2016148183A (ru) 2018-06-13
LT3057589T (lt) 2017-11-27
US20170143709A1 (en) 2017-05-25
CA2948598C (fr) 2021-06-08
ES2649492T3 (es) 2018-01-12
US9814712B2 (en) 2017-11-14
EP3057589A1 (fr) 2016-08-24
WO2015171005A1 (fr) 2015-11-12
JP2017518979A (ja) 2017-07-13
NZ726132A (en) 2019-02-22
TN2016000498A1 (en) 2018-04-04
IL248855A0 (en) 2017-01-31
KR102298676B1 (ko) 2021-09-07
DK3057589T3 (da) 2017-11-13
AU2014393490A1 (en) 2016-11-24
CA2948598A1 (fr) 2015-11-12
RU2695647C2 (ru) 2019-07-25
CN106456637B (zh) 2020-06-09
RU2016148183A3 (fr) 2018-06-13
EP3057589B1 (fr) 2017-08-02
PL3057589T3 (pl) 2018-01-31

Similar Documents

Publication Publication Date Title
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
WO2015165964A8 (fr) Traitement et prévention de la maladie d'alzheimer
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
TH167851B (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
MX2019013912A (es) Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4.
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
MA39188A1 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
FR3023166B1 (fr) Utilisation d'une composition pharmaceutique renfermant une pectine a titre de principe actif, dans la prevention et/ou le traitement des lesions cutanees impliquant un caractere inflammatoire
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
TH168999A (th) สารยับยั้งของ rorc2 ประเภทเฮเทอโรไบไซโคลแอริล และวิธีการใช้ของมัน